JP2020096630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020096630A5 JP2020096630A5 JP2020025935A JP2020025935A JP2020096630A5 JP 2020096630 A5 JP2020096630 A5 JP 2020096630A5 JP 2020025935 A JP2020025935 A JP 2020025935A JP 2020025935 A JP2020025935 A JP 2020025935A JP 2020096630 A5 JP2020096630 A5 JP 2020096630A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cldn6
- recombinant nucleic
- cell
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003859 Claudin-6 Human genes 0.000 claims description 38
- 108090000229 Claudin-6 Proteins 0.000 claims description 38
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 230000005754 cellular signaling Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000037452 priming Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108020005202 Viral DNA Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000004507 artificial chromosome Anatomy 0.000 claims 1
- 239000013601 cosmid vector Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 25
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 19
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 19
- 108091008874 T cell receptors Proteins 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021190855A JP7451858B2 (ja) | 2014-04-01 | 2021-11-25 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2014/000868 | 2014-04-01 | ||
| EP2014000868 | 2014-04-01 | ||
| EPPCT/EP2014/072864 | 2014-10-24 | ||
| EP2014072864 | 2014-10-24 | ||
| JP2017503063A JP6726656B2 (ja) | 2014-04-01 | 2015-03-30 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503063A Division JP6726656B2 (ja) | 2014-04-01 | 2015-03-30 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021190855A Division JP7451858B2 (ja) | 2014-04-01 | 2021-11-25 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020096630A JP2020096630A (ja) | 2020-06-25 |
| JP2020096630A5 true JP2020096630A5 (https=) | 2020-08-06 |
| JP6985440B2 JP6985440B2 (ja) | 2021-12-22 |
Family
ID=52745896
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503063A Active JP6726656B2 (ja) | 2014-04-01 | 2015-03-30 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
| JP2020025935A Active JP6985440B2 (ja) | 2014-04-01 | 2020-02-19 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
| JP2021190855A Active JP7451858B2 (ja) | 2014-04-01 | 2021-11-25 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503063A Active JP6726656B2 (ja) | 2014-04-01 | 2015-03-30 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021190855A Active JP7451858B2 (ja) | 2014-04-01 | 2021-11-25 | クローディン６特異的免疫受容体およびｔ細胞エピトープ |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10370423B2 (https=) |
| EP (3) | EP3514172B1 (https=) |
| JP (3) | JP6726656B2 (https=) |
| CN (3) | CN113150109A (https=) |
| AU (3) | AU2015239683B2 (https=) |
| CA (1) | CA2942459C (https=) |
| CY (1) | CY1121539T1 (https=) |
| DK (3) | DK3514172T3 (https=) |
| ES (3) | ES2784537T3 (https=) |
| FI (1) | FI3708579T3 (https=) |
| HR (2) | HRP20190472T4 (https=) |
| HU (3) | HUE067504T2 (https=) |
| LT (2) | LT3708579T (https=) |
| ME (1) | ME03407B (https=) |
| MX (1) | MX376026B (https=) |
| PL (3) | PL3514172T3 (https=) |
| PT (3) | PT3514172T (https=) |
| RS (2) | RS58627B2 (https=) |
| SI (3) | SI3514172T1 (https=) |
| SM (1) | SMT201900262T1 (https=) |
| WO (1) | WO2015150327A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3305813T3 (da) | 2009-11-11 | 2020-04-20 | Astellas Pharma Inc | Antistoffer, der er specifikke for claudin 6 (cldn6) |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| RU2016122041A (ru) | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые анти-клаудин антитела и способы их применения |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| AU2015346350C1 (en) | 2014-11-14 | 2022-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thyroglobulin t cell receptors |
| CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药（上海）有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| WO2016180468A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| WO2016180467A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| MA55153A (fr) | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| SG10202012157QA (en) * | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| WO2018011421A1 (en) | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| CN110461881B (zh) * | 2017-03-27 | 2023-06-23 | 诺伊尓免疫生物科技株式会社 | 嵌合抗原受体 |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| NO20210351A1 (en) * | 2017-09-18 | 2021-03-18 | Univ California | Claudin6 antibodies and methods of treating cancer |
| NZ762505A (en) | 2017-09-29 | 2026-03-27 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CA3118789A1 (en) | 2018-11-06 | 2020-05-14 | Genmab A/S | Antibody formulation |
| CA3119188A1 (en) * | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | T cell receptors specific for mesothelin and their use in immunotherapy |
| EP4198057A1 (en) * | 2018-12-05 | 2023-06-21 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
| FI3920939T3 (fi) * | 2019-02-08 | 2025-01-03 | Biontech Cell & Gene Therapies Gmbh | Kimeerisiä anigeenireseptori-modifioituja soluja hoitamaan CLDN6-ekspressoivia syöpiä |
| WO2020180648A1 (en) * | 2019-03-01 | 2020-09-10 | Gritstone Oncology, Inc. | Selection of t cell receptors |
| DK3941946T3 (da) | 2019-03-20 | 2025-03-24 | Univ California | Claudin-6-antistoffer og lægemiddelkonjugater |
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| EP4100059A1 (en) | 2020-02-04 | 2022-12-14 | Genmab A/S | Antibodies for use in therapy |
| MX2023005386A (es) | 2020-11-11 | 2023-05-23 | BioNTech SE | Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina. |
| US20240216427A1 (en) * | 2020-12-30 | 2024-07-04 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1) |
| BR112023027006A2 (pt) | 2021-06-21 | 2024-03-12 | BioNTech SE | Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| EP4395823A4 (en) * | 2021-09-03 | 2025-07-16 | Novarock Biotherapeutics Ltd | BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN |
| CN119053340A (zh) | 2021-10-06 | 2024-11-29 | 健玛保 | 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症 |
| EP4413040A1 (en) | 2021-10-06 | 2024-08-14 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
| WO2023064899A1 (en) * | 2021-10-14 | 2023-04-20 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors against claudin 6 |
| WO2023218051A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| EP4522654A1 (en) | 2022-05-12 | 2025-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| EP4522657A1 (en) | 2022-05-12 | 2025-03-19 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| CN115232207B (zh) * | 2022-05-19 | 2023-06-13 | 河南大学 | 抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用 |
| WO2024165057A1 (en) * | 2023-02-07 | 2024-08-15 | LaNova Medicines Limited | Antibodies and antibody-drug conjugates targeting claudin 6 |
| CN121620391A (zh) | 2023-04-06 | 2026-03-06 | 金麦安博股份有限公司 | 用于治疗癌症的针对pd-l1和cd137的多特异性结合剂 |
| IL324834A (en) | 2023-05-25 | 2026-01-01 | Univ California | Dosage of claudin-6 conjugates for cancer treatment |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| CN118812714B (zh) * | 2024-08-21 | 2025-05-27 | 广州百吉生物制药有限公司 | 一种紧密连接蛋白抗体b3及其应用 |
| CN119320451B (zh) * | 2024-08-21 | 2025-05-16 | 百吉生物医药(广州)股份有限公司 | 一种紧密连接蛋白抗体d03及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| EP1945246A4 (en) * | 2005-09-22 | 2009-03-11 | Irun R Cohen | IMMUNOGENIC FRAGMENTS OF CONSTANT DOMAINS OF THE T CELL RECEPTOR AND PEPTIDES DERIVED THEREFROM |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| JPWO2008114733A1 (ja) * | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | 抗Ｃｌａｕｄｉｎ−４抗体 |
| EP2241578B1 (en) * | 2008-01-11 | 2016-04-20 | The University of Tokyo | Anti-cldn6 antibody |
| SMT202300421T1 (it) * | 2009-02-20 | 2024-01-10 | Astellas Pharma Inc | Metodi e composizioni per la diagnosi e il trattamento del cancro |
| DK3305813T3 (da) * | 2009-11-11 | 2020-04-20 | Astellas Pharma Inc | Antistoffer, der er specifikke for claudin 6 (cldn6) |
| EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| US8840902B2 (en) * | 2010-03-16 | 2014-09-23 | Biontech Ag | Tumor vaccination involving a humoral immune response against self-proteins |
| WO2011130343A1 (en) * | 2010-04-13 | 2011-10-20 | Sigma-Aldrich Co. | Biosensors comprising protein-binding domains and fluorescent proteins |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| ES2602743T3 (es) * | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| FR2970083B1 (fr) | 2011-01-05 | 2013-02-15 | Leosphere | Procede et dispositif de determination des mouvements d'un fluide a partir de mesures a distance de vitesses radiales. |
| ES2989943T3 (es) * | 2011-05-13 | 2024-11-28 | Astellas Pharma Inc | Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6 |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
-
2015
- 2015-03-30 PT PT191512383T patent/PT3514172T/pt unknown
- 2015-03-30 AU AU2015239683A patent/AU2015239683B2/en active Active
- 2015-03-30 EP EP19151238.3A patent/EP3514172B1/en active Active
- 2015-03-30 HU HUE20160141A patent/HUE067504T2/hu unknown
- 2015-03-30 FI FIEP20160141.6T patent/FI3708579T3/fi active
- 2015-03-30 PT PT201601416T patent/PT3708579T/pt unknown
- 2015-03-30 SI SI201531143T patent/SI3514172T1/sl unknown
- 2015-03-30 PL PL19151238T patent/PL3514172T3/pl unknown
- 2015-03-30 DK DK19151238.3T patent/DK3514172T3/da active
- 2015-03-30 PL PL15712657T patent/PL3126381T5/pl unknown
- 2015-03-30 US US15/124,640 patent/US10370423B2/en active Active - Reinstated
- 2015-03-30 LT LTEP20160141.6T patent/LT3708579T/lt unknown
- 2015-03-30 CN CN202110278993.9A patent/CN113150109A/zh active Pending
- 2015-03-30 RS RS20190361A patent/RS58627B2/sr unknown
- 2015-03-30 JP JP2017503063A patent/JP6726656B2/ja active Active
- 2015-03-30 HR HRP20190472TT patent/HRP20190472T4/hr unknown
- 2015-03-30 CA CA2942459A patent/CA2942459C/en active Active
- 2015-03-30 ES ES19151238T patent/ES2784537T3/es active Active
- 2015-03-30 EP EP20160141.6A patent/EP3708579B1/en active Active
- 2015-03-30 MX MX2016012713A patent/MX376026B/es active IP Right Grant
- 2015-03-30 ME MEP-2019-67A patent/ME03407B/me unknown
- 2015-03-30 SM SM20190262T patent/SMT201900262T1/it unknown
- 2015-03-30 ES ES20160141T patent/ES2982838T3/es active Active
- 2015-03-30 PT PT15712657T patent/PT3126381T/pt unknown
- 2015-03-30 DK DK20160141.6T patent/DK3708579T3/da active
- 2015-03-30 CN CN201580017607.3A patent/CN106459165B/zh active Active
- 2015-03-30 LT LTEP15712657.4T patent/LT3126381T/lt unknown
- 2015-03-30 PL PL20160141.6T patent/PL3708579T3/pl unknown
- 2015-03-30 CN CN202110279207.7A patent/CN113150110A/zh active Pending
- 2015-03-30 DK DK15712657.4T patent/DK3126381T4/da active
- 2015-03-30 RS RS20240864A patent/RS65784B1/sr unknown
- 2015-03-30 HU HUE19151238A patent/HUE050355T2/hu unknown
- 2015-03-30 EP EP15712657.4A patent/EP3126381B2/en active Active
- 2015-03-30 WO PCT/EP2015/056899 patent/WO2015150327A1/en not_active Ceased
- 2015-03-30 HR HRP20240926TT patent/HRP20240926T1/hr unknown
- 2015-03-30 HU HUE15712657 patent/HUE044515T2/hu unknown
- 2015-03-30 SI SI201530629T patent/SI3126381T2/sl unknown
- 2015-03-30 ES ES15712657T patent/ES2717530T5/es active Active
- 2015-03-30 SI SI201532019T patent/SI3708579T1/sl unknown
-
2019
- 2019-04-02 CY CY20191100366T patent/CY1121539T1/el unknown
- 2019-06-18 US US16/444,510 patent/US11345731B2/en active Active
- 2019-07-31 AU AU2019210582A patent/AU2019210582B2/en active Active
-
2020
- 2020-02-19 JP JP2020025935A patent/JP6985440B2/ja active Active
-
2021
- 2021-05-31 AU AU2021203528A patent/AU2021203528B2/en active Active
- 2021-11-25 JP JP2021190855A patent/JP7451858B2/ja active Active
-
2022
- 2022-04-04 US US17/712,562 patent/US12559531B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020096630A5 (https=) | ||
| JP7227290B2 (ja) | キメラ抗原受容体、組成物及び方法 | |
| US20230241172A1 (en) | Interleukin-18 variants and methods of use | |
| KR102223873B1 (ko) | 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용 | |
| CN108715859B (zh) | 靶向cd22的嵌合抗原受体及其应用 | |
| CN111925451B (zh) | 一种靶向bcma的嵌合抗原受体(car)及其应用 | |
| KR20180054590A (ko) | 항글리피칸-3 항체 및 이의 응용 | |
| WO2019137518A1 (zh) | 以cd19为靶点的特异性抗体、car-nk细胞及其制备方法和应用 | |
| CN114409797B (zh) | 重组抗体及其应用 | |
| JP7138989B1 (ja) | メソテリンに特異的に結合する抗メソテリンキメラ抗原受容体 | |
| KR20210043623A (ko) | Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포 | |
| US20230357355A1 (en) | Cspg4-targeting humanized chimeric antigen receptor, immune effector cell expressing chimeric antigen receptor, and applications thereof | |
| EP4435012A1 (en) | Bcma-targeting chimeric antigen receptor and use thereof | |
| CN116589584A (zh) | 靶向人Nectin4蛋白的抗体或其片段和应用 | |
| CN110981960B (zh) | 一种嵌合抗原受体（car）及其应用 | |
| JP2021536256A (ja) | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 | |
| CN110938148A (zh) | 靶向cd19和cd22嵌合抗原受体 | |
| CN114920841B (zh) | 抗cd87抗体及其特异性嵌合抗原受体 | |
| CN116284419A (zh) | 靶向人gucy2c蛋白的单克隆抗体及其应用 | |
| JP7054143B2 (ja) | キメラ抗原受容体、及びその利用 | |
| CN114685659B (zh) | Cd22特异性人源化抗体及利用其的嵌合抗原受体 | |
| EP4301402A1 (en) | Bispecific antibodies enhancing cell mediated immune responses | |
| WO2022150379A1 (en) | Nk cell engager molecules and methods of use | |
| JP2023549441A5 (https=) | ||
| WO2026007830A1 (zh) | 一种靶向cd7的纳米抗体及其应用 |